The global next generation sequencing (NGS) sample preparation market size was valued at USD 2.76 billion in 2018 and is expected to grow at a CAGR of 11.19% during the forecast period. The anticipated growth in revenue can be attributed to the development of products that enable the generation of high-quality libraries of sufficient quality as well as the yield for successful sequencing.
With the improvements in the sequencing technologies for the capacity expansion, the boundaries for the sample preparation protocols are also being pushed. Efficient pre-sequencing steps such as target enrichment and library preparation lead to the generation of high quality, accurate sequencing data. Continuous innovations in the field of NGS sample preparation have led to the availability of standardized sample preparation protocols thereby driving the NGS sample preparation market significantly.
With the generation of a large amount of data, the tracking, and organization of sequencing sample data has become a major challenge in most of the large-scale laboratories. Therefore, the development of electronic solutions to manage NGS samples has propelled the market growth.
These electronic solutions include information management software such as electronic lab notebooks (ELNs), spreadsheets, automation, and whole laboratory information management systems (LIMSs). In addition, tagging NGS samples with genetic (DNA) barcodes during library preparation allows efficient tracing of sample reads to the original sample types.
The evolution of integrated and automated informatics and mechanical protocols have brought about automation in NGS sample preparation. Automation has significantly impacted the growth of NGS sample preparation market as it enhances sequencing speed & capacity, and sample tracking. Automated robots can easily find reagents and operate on the sample in accordance with the system requirements. In addition, cameras and lasers installed in the system easily locate samples at each step during sequencing.
Companies are also focused on enhancing the speed of quality library preparation. Therefore, key players are engaged in the development of efficient sample preparation protocols that ensure the success of sequencing irrespective of the input. PerkinElmer has used artificial intelligence to improve the overall NGS workflow. The company’s IntelliChip technology minimizes variance and standard deviation for different assay runs to optimize the overall process.
PerkinElmer has also collaborated with 10X Genomics to improve the quantification and extraction of different types of input materials. The collaboration aimed to combine 10x Genomics’ Chromium Genome Solution with PerkinElmer’s LabChip GX Touch Nucleic Acid Analyzer, and chemagic technology to develop an automated workflow for sample preparation.
Semi-automated library preparation accounted for the largest share in 2018 and is expected to dominate the overall market throughout the forecast period. This is because of the use of a combination of manual and automated approaches for library preparation. In the combination method, automation is used for the ligation of molecular barcoded adaptors, end repair, and purification reactions to carry out ligation of SOLiD adaptors to the processed DNA.
The manual steps of semi-automated library preparation methods include gel purification and library amplification. Apart from this, the introduction of automated library preparation solutions is expected to drive segment growth. Innovation in the automation to enable minimal hands-on time to implement complicated library preparation protocols will allow labs to be more productive with their headcount. However, a breakthrough is still required to increase the adoption of automated protocols in labs that cannot procure a robot.
Oncology segment accounted for the largest share in 2018 owing to the presence of several players engaged in the development of oncology targeted panels. These panels pronounce the demand for sample preparation solutions. Companies are partnering with the leading biotechnology firms for the development of oncology companion diagnostics products.
For instance, in April 2018 Illumina collaborated with Bristol-Myers Squibb to manufacture and market companion diagnostics assays for the latter’s oncology immunotherapies. Illumina also partnered with Loxo Oncology in April 2018 for the development of NGS-based pan-cancer companion diagnostic solutions for solid tumors.
Similarly, other market players are also striving to enhance their product offerings for oncology companion diagnostics. In this regard, Biodesix, Inc. signed an agreement with Thermo Fisher Scientific in July 2019 to develop an NGS assay for Non-small Cell Lung Cancer (NSCLC). The company also seeks to get FDA-Premarket approval (PMA) classification for the test.
Clinical research segment is projected to grow with the highest CAGR throughout the forecast period. This is due to the high adoption of NGS in cancer research, specifically in the discovery of new cancer-related genes, study of tumor heterogeneity, and identification of alterations that contribute to tumorigenesis. Rise in penetration of NGS technology in the laboratories owing to the increase in funding from government agencies is expected to boost revenue generation.
In addition, the availability of clinical research solutions through market entities such as Illumina, Thermo Fisher Scientific Corporation, and Agilent Technologies for target enrichment & detection is anticipated to provide growth opportunities for this segment. The prominent cancer research panels offered by Illumina include TruSight RNA Fusion, TruSight Tumor 170, TruSight Oncology UMI Reagents, TruSight RNA Pan-Cancer, TruSight Tumor 15, TruSight Myeloid Sequencing Panel, TruSight Cancer Sequencing Panel, and TruSight Oncology 500.
North America accounted for the largest share of revenue in the global market space and is expected to maintain this dominant position in the coming years. The simultaneous developments of next-generation sequencing, personalized medicine and companion diagnostics in the region are attributive towards the projected market growth.
Furthermore, the presence of high R&D investment, technologically advanced healthcare research framework and the presence of substantial players are driving the biotechnology and ancillary markets in this region.
Second, only to North America, Asian countries are projected to witness significant growth in this market. Changes in the regulatory structure, affordability pattern and technological advances in the developing economies of this region are attributive to the estimated growth trend. Furthermore, presence of the diseased population increases the clinical trial associated activities in the region, thus driving demand for NGS solutions.
Key players operating in the market include Agilent Technologies.; BGI; Biomatters Ltd.; Bio-Rad Laboratories, Inc.; Congenica Ltd; DNASTAR; Eurofins Scientific; F. Hoffmann-La Roche Ltd; Foundation Medicine; Genomatix GmbH; Illumina; Macrogen; Myriad Genetics; Oxford Nanopore Technologies; Pacific Biosciences of California; Partek Incorporated; Perkin Elmer; PierianDx; QIAGEN; Quest Diagnostics Incorporated; and Thermo Fisher Scientific.
These players are engaged in new product development and strategic alliances to maintain the market share. Collaborations with the other companies working across the workflow of NGS technology including data analysis and sequencing would aid in the growth of the application of this technology for diagnosis and prognosis of chronic diseases.
Attribute |
Details |
Base year for estimation |
2018 |
Actual estimates/Historic data |
2014 - 2018 |
Forecast period |
2019 - 2025 |
Market representation |
Revenue in USD Million & CAGR from 2019 to 2025 |
Regional scope |
North America, Europe, Asia Pacific, Latin America, MEA |
Country scope |
U.S., Canada, Germany, UK ,Japan, China, Brazil, South Africa |
Report coverage |
Revenue forecast, competitive landscape, growth factors, and trends |
15% free customization scope (equivalent to 5-analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth and provides an analysis on the market trends in each of the submarkets from 2014 to 2025. For the purpose of this study, Grand View Research, Inc. has segmented the global next generation sequencing sample preparation market report on the basis of workflow, application, end use, and region:
Workflow Outlook (Revenue, USD Million, 2014 - 2025)
NGS Library Preparation Kits
Semi-automated Library Preparation
Automated Library Preparation
Clonal Amplification
Application Outlook (Revenue, USD Million, 2014 - 2025)
Oncology
Clinical Investigation
Reproductive Health
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Consumer Genomics
End-Use Outlook (Revenue, USD Million, 2014 - 2025)
Academic Research
Clinical Research
Hospitals & Clinics
Pharma & Biotech Entities
Other Users
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
U.S.
Canada
Europe
Germany
UK
Asia Pacific
Japan
China
Latin America
Brazil
MEA
South Africa
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.